Brind.

Jupiter Neurosciences is a clinical-stage pharmaceutical company.

3 reports, 0 independent Updated Jul 1

Gone quiet

Reports: 3
Developments: 2
Repetition: 33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Jupiter Neurosciences is a clinical-stage pharmaceutical company.

Who's involved

What this event is mainly about

Juns Company

How it developed

Newest first. Tap a step to see who reported it.

Jul 1Jupiter Neurosciences achieved clinical-stage status on July 1, 2025.
Jun 23Annika Sörenstam endorses Juns' products targeting LPGA athletes.

Keep exploring

The entities involved

Juns
company based in Japan

Nothing else this week.
Company
Direct Mail Division of FSSI
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Mon 13:17
- A partnership with BARDA has accelerated the development of SCY-247 for the company.Mon 13:17

Coverage

Newest first; wire copies grouped

Jul 1Unknown outlet
Jun 27Unknown outlet
Jun 23Unknown outlet